Skip to content

New Therapeutic System of Ruptured Intracranial Aneurysms Based on Big Data From Chinese Population

New Therapeutic System of Ruptured Intracranial Aneurysms Based on Big Data From Chinese Population

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03153748
Acronym
NATIONAL-2
Enrollment
10000
Registered
2017-05-15
Start date
2016-07-01
Completion date
2020-12-31
Last updated
2017-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Subarachnoid Hemorrhage, Aneurysmal

Keywords

Treatment strategy

Brief summary

This study aims at clarifying the current situation of Emergency treatment of aneurysmal subarachnoid hemorrhage (SAH) in China, and analyzing the safety and efficacy of the treatment strategy between interventional treatment and open surgery, so as to improve the diagnosis and treatment of aneurysmal SAH.

Interventions

None listed

Sponsors

Changhai Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* patients presented with subarachnoid hemorrhage on CT or lumbar puncture. * the intracranial hemorrhage was caused by rupture of aneurysm and was confirmed on CTA、MRA or DSA. * patients willing to participate in this clinical trial and attach to regular follow up.

Exclusion criteria

* intracranial aneurysm correlating to AVM. * dissection, false, traumatic and infectious aneurysms. * the rupture of the aneurysm can not be confirmed on CTA、MRA or DSA. * patients unwilling to participate in this clinical trial and attach to regular follow up.

Design outcomes

Primary

MeasureTime frameDescription
mRS score1 year after treatmentthe mRS score after treatment
cure rate6 months after treatmentthe proportion of the cured-patient according Raymond Class

Secondary

MeasureTime frameDescription
recurrence ratethrough study completion, an average of 1 yearthe proportion of the recurrence of the patient
complication ratethrough study completion, an average of 1 yearthe proportion of complication happened after treatment including ischemic, hemorrhage, retreat, and so on

Countries

China

Contacts

Primary ContactPengfei Yang, MD
15921196312@163.com+86 15921196312
Backup ContactHongjian Zhang, MD
chzhanghj2012@me.com+86 13961616656

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026